Patent details

EP3033339 Title: 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES

Basic Information

Publication number:
EP3033339
PCT Application Number:
EP2014001281
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP147274013
PCT Publication Number:
WO2015022038
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES
French Title of Invention:
DÉRIVÉS DE LA CYCLOPENTYLEAMINE 3-SUBSTITUÉS
German Title of Invention:
IN 3-STELLUNG SUBSTITUIERTE CYCLOPENTYLAMIN DERIVATE
SPC Number:

Dates

Filing date:
12/05/2014
Grant date:
28/02/2018
EP Publication Date:
22/06/2016
PCT Publication Date:
19/02/2015
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
28/02/2018
EP B1 Publication Date:
28/02/2018
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
12/05/2018
Expiration date:
12/05/2034
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
21/02/2018
 
 

Name:
Merck Patent GmbH
Address:
Frankfurter Strasse 250, 64293 Darmstadt, Germany (DE)

Inventor

1

Name:
STAEHLE, Wolfgang
Address:
Germany (DE)

2

Name:
TSAKLAKIDIS, Christos
Address:
Germany (DE)

3

Name:
LEUTHNER, Birgitta
Address:
Germany (DE)

Priority

Priority Number:
13004080
Priority Date:
16/08/2013
Priority Country:
European Patent Office (EPO) (EP)

Classification

IPC classification:
A61K 31/4192; A61K 31/423; A61K 31/4245; A61K 31/428; A61K 31/4439; A61K 31/519; A61P 25/00; A61P 31/00; A61P 35/00; C07D 249/04; C07D 271/10; C07D 413/12; C07D 413/14; C07D 417/12; C07D 487/04;

Publication

European Patent Bulletin

Issue number:
201809
Publication date:
28/02/2018
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/09/2018 Outgoing Correspondence 1